1,12- bis(4- methyl- 5- (2- hydroxyethyl)thiazol- 3- ium- 3- yl)dodecane
an antimalarial
Also Known As:
1,12-bis(4-methyl-5-(2-hydroxyethyl)thiazol-3-ium-3-yl)dodecane dibromide; 1,12-bisMHTD; SAR 97276; SAR-97276; SAR97276; albitiazolium
Networked: 5
relevant articles (1 outcomes,
3 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
| 1. | Vial, Henri J:
3 articles
(09/2014 - 06/2009)
|
| 2. | Wein, Sharon:
3 articles
(09/2014 - 06/2009)
|
| 3. | Maynadier, Marjorie:
2 articles
(09/2014 - 05/2012)
|
| 4. | Peyrottes, Suzanne:
2 articles
(09/2014 - 05/2012)
|
| 5. | Abdulla, Salim:
1 article
(01/2017)
|
| 6. | Bonkian, Léa Nadège:
1 article
(01/2017)
|
| 7. | Bouyou-Akotet, Marielle:
1 article
(01/2017)
|
| 8. | Cantalloube, Cathy:
1 article
(01/2017)
|
| 9. | Djeriou, Elhadj:
1 article
(01/2017)
|
| 10. | Held, Jana:
1 article
(01/2017)
|
Related Diseases
| 1. | Malaria
08/01/2012
- " This has given rise to albitiazolium, which is currently in phase II clinical trials to cure severe malaria. " 01/01/2017
- " Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patients." 09/01/2014
- " Here, we provide new insight into the choline analogue albitiazolium, which is currently being clinically tested against severe malaria. " 06/01/2009
- " 1,12-Bis[5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium]dodecane dibromide (SAR97276, T3) is a new antimalarial drug, which is currently being evaluated in clinical trials for severe malaria. " 05/24/2012
- " We report herein the design, synthesis, and biological screening of a series of 15 disulfide prodrugs as precursors of albitiazolium bromide (T3/SAR97276, compound 1), a choline analogue which is currently being evaluated in clinical trials (phase II) for severe malaria. "
|
|
Related Drugs and Biologics